![]() | |
Clinical data | |
---|---|
Pronunciation | /ˌtəˈnoʊfəvɪər ˌæləˈfɛnəmaɪd/ |
Trade names | Vemlidy Genvoya (with elvitegravir, cobicistat and emtricitabine) Odefsey (with emtricitabine and rilpivirine) Descovy (with emtricitabine) Symtuza (with darunavir, cobicistat, and emtricitabine) |
Other names | GS-7340 |
AHFS/ Drugs.com | Monograph |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth ( tablets) |
Drug class | Reverse transcriptase inhibitor [2] |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | ~80% [4] |
Elimination half-life | 0.51 hour |
Excretion | Feces (31.7%), urine (<1%) |
Identifiers | |
| |
Chemical and physical data | |
Formula | C21H29N6O5P |
Molar mass | 476.474 g·mol−1 |
3D model ( JSmol) | |
| |
|
Tenofovir alafenamide, sold under the brand name Vemlidy, is a medication for the treatment of chronic hepatitis B in those with compensated liver disease. [5] It is taken by mouth. [5] It can be used in people over the age of 11. [2] Hepatitis B may worsen after stopping the medication. [5]
Common side effects include headache, nausea, and tiredness. [2] Other side effects may include lactic acidosis. [5] It is not recommended in severe liver problems. [5] Tenofovir alafenamide is converted by the body to tenofovir, by which it works. [2] This than blocks reverse transcriptase which prevents the virus from multiplying. [2]
Tenofovir alafenamide was approved for use in the United States in 2016 and Europe in 2017. [5] [2] In the United States it costs about 1,300 USD per month as of 2021. [6] In the United Kingdom this amount costs the NHS about £325 and in Canada it is about 600 CAD. [7] [8]
{{
cite book}}
: CS1 maint: date format (
link)